"Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. This is the largest trial ever conducted in...
Contactless Health Screening
Ehave acquires License covering G-20 Countries for all Psychedelic use, AI-Powered Telehealth Technology To Capture Physiological Vitals From Vastmindz; Prepares To Run Testing On...
Focusing on novel uses, production and delivery forms of psilocybin as a next generation solution for mental illness, substance abuse and neurological disordersAdvancing to FDA clinical studies for methamphetamine use disorder and...
LIVE QUOTE
Toronto | July 28, 2021 – Today, NEO welcomes its newest corporate listing partner, Biomind Labs Inc. (“Biomind”), as it makes its public markets debut on the NEO Exchange. A...
Progress in the development of DMT-assisted therapy for the treatment of depression
LONDON, Aug. 9, 2021 /CNW/ -- Small Pharma Inc. (TSXV: DMT) (the "Company" or "Small Pharma"), a...
